ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7
Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds
Targeting One Specific Protein Can Double PFS; Triple Overall Survival
Revlimid Maintenance Therapy Delayed Progression by 90%
Drug Effectiveness Weakens After Three Years, Study Says
Nexavar Improves PFS In HER-2 Negative Breast Cancer
Xgeva Significantly Increases Bone Metastasis-Free Survival
U.S. Patients Use More Chemotherapy, Less Emergency Care than Canadians
Urocidin May Provide Alternative To Cystectomy in BCG Cancers
Clinical Trials Approved By NCI CTEP Last Month
Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors
Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
